{"id":3867,"date":"2023-02-10T17:21:00","date_gmt":"2023-02-10T17:21:00","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&p=3867"},"modified":"2023-02-10T17:56:44","modified_gmt":"2023-02-10T17:56:44","slug":"method-for-diagnosis-prognosis-and-determination-of-treatment-for-cutaneous-t-cell-lymphoma","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/method-for-diagnosis-prognosis-and-determination-of-treatment-for-cutaneous-t-cell-lymphoma\/","title":{"rendered":"Method for Diagnosis, Prognosis and Determination of Treatment for Cutaneous T-cell Lymphoma"},"content":{"rendered":"

Method for Diagnosis, Prognosis and Determination of Treatment for Cutaneous T-cell Lymphoma<\/p>\n

\n
\n
\n

<\/h2>\n<\/section>\n<\/div>\n<\/div>\n
\n
\n
\n

<\/h2>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div><\/div><\/div>

Inventors: <\/strong>Brittany L. O. Dulmage; Larisa J. Geskin; Louis D. Falo Jr<\/p>\n

Patent Number:<\/strong> 11,067,577<\/p>\n

\n
\n
\n

Abstract<\/h3>\n
\n
\n
The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and\/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and\/or design and monitor treatment.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div>
<\/div>
<\/div>